Research and Markets ( http://www.researchandmarkets.com/re...peline_insight : http://cts.businesswire.com/ct/CT?id...3ba3f68c522856 ) has announced the addition of the " Pipeline Insight: Colorectal Cancer - Growing Trend Towards Personalized Medicine : http://cts.businesswire.com/ct/CT?id...960094a6140292 " report to their offering. CRC incidence will be over 490,000 cases by 2018 in the seven major markets. This large patient base will translate into a high commercial potential for the development of novel, more effective therapies. Currently, there are 77 agents in development for CRC, 4 of which are in late-phase development. Collectively, they are forecast to achieve sales of $1,398m by 2018. Scope - Examination of the CRC pipeline with in-depth clinical and
More...
More...